Page 50 - Read Online

Matrone et al. J Cancer Metastasis Treat 2021;7:23 https://dx.doi.org/10.20517/2394-4722.2021.47 Page 17 of 19

2010;16:5260-8. DOI PubMed PMC
62. Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid
carcinoma: MC057H. J Clin Endocrinol Metab 2014;99:1687-93. DOI PubMed PMC
63. De Falco V, Buonocore P, Muthu M, et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated
with thyroid cancer. J Clin Endocrinol Metab 2013;98:E811-9. DOI PubMed
64. Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in
advanced medullary thyroid cancer. Clin Cancer Res 2016;22:44-53. DOI PubMed
65. Sun Y, Du F, Gao M, et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer.
Thyroid 2018;28:1455-61. DOI PubMed
66. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a
randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41. DOI PubMed PMC
67. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46.
DOI PubMed PMC
68. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor
growth following oral administration. Cancer Res 2002;62:4645-55. PubMed
69. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks
oncogenic RET kinases. Cancer Res 2002;62:7284-90. PubMed
70. Kreissl MC, Bastholt L, Elisei R, et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer:
post hoc analysis from the ZETA trial. J Clin Oncol 2020;38:2773-81. DOI PubMed PMC
71. Massicotte MH, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid
carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 2014;170:575-82. DOI PubMed
72. Chougnet CN, Borget I, Leboulleux S, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical
trial: results from a French cohort. Thyroid 2015;25:386-91. DOI PubMed
73. Ramos HE, Hecht F, Berdelou A, et al. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Endocrine 2021;71:434-42. DOI PubMed
74. Valerio L, Bottici V, Matrone A, et al. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Endocr Relat Cancer 2020;27:97-110. PubMed
75. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin
Oncol 2007;25:5121-7. DOI PubMed
76. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825-35.
DOI PubMed
77. Hu M, Subbiah M, Wirth LJ, et al. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts)
with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC). Ann Oncol 2020;31:S1084. DOI
78. Hu MI, Elisei R, Dedecjus M, et al. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Endocr Relat Cancer 2019;26:241-50. DOI PubMed
79. Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated
medullary thyroid carcinoma. Clin Cancer Res 2013;19:4239-48. DOI PubMed PMC
80. Paepegaey AC, Cochand-Priollet B, Louiset E, et al. Long-term control of hypercortisolism by vandetanib in a case of medullary
thyroid carcinoma with a somatic RET mutation. Thyroid 2017;27:587-90. DOI PubMed
81. Pitoia F, Bueno F, Schmidt A, Lucas S, Cross G. Rapid response of hypercortisolism to vandetanib treatment in a patient with
advanced medullary thyroid cancer and ectopic Cushing syndrome. Arch Endocrinol Metab 2015;59:343-6. DOI PubMed
82. Nella AA, Lodish MB, Fox E, et al. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an
adolescent patient. J Clin Endocrinol Metab 2014;99:3055-9. DOI PubMed PMC
83. Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med
2013;369:584-6. DOI PubMed
84. Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev
2019;40:1573-604. DOI PubMed PMC
85. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with
medullary thyroid cancer. J Clin Oncol 2011;29:2660-6. DOI PubMed PMC
86. Sherman SI, Clary DO, Elisei R, et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients
with progressive, metastatic medullary thyroid cancer. Cancer 2016;122:3856-64. DOI PubMed
87. Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with
radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017;28:2813-9. DOI PubMed PMC
88. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer 2009;45:228-47. DOI PubMed
89. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with
advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab
2013;98:2401-8. DOI PubMed
90. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with
which drug--those are the questions. J Clin Endocrinol Metab 2014;99:4390-6. DOI PubMed PMC
91. Brose MS, Bible KC, Chow LQM, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer